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bo the Editor: Because clinical features of Takotsubo cardiomyop-
thy (TC) mimic those of anterior acute myocardial infarction
AMI) (1), the differential diagnosis is important in selecting the
ppropriate treatment strategy, especially in the acute phase. This
tudy assessed the value of the electrocardiogram (ECG) for
iscriminating TC from anterior AMI. We retrospectively com-
ared admission ECGs of 33 patients with TC with those of 342
atients with a first anterior AMI who had ST-segment elevation
f 1.0 mm in at least 2 contiguous precordial leads. All patients
ere admitted within 6 h of symptom onset. Patients with left or
ight bundle branch block, left ventricular hypertrophy, or atrial
brillation were excluded. All patients with TC fulfilled the Mayo
linic diagnosis criteria for TC (2); emergency coronary angiog-
aphy was performed in 25 patients (76%) and emergency left
entriculography in 23 (70%). The diagnosis of anterior AMI was
ased on typical chest pain lasting for at least 30 min and a typical
ncrease in serum creatine kinase levels to more than twice the
pper limit of normal, as well as precordial ST-segment elevation
n the admission ECG, as described previously. All patients with
nterior AMI underwent emergency coronary angiography, and
he presence of obstruction, severe stenosis, or intracoronary
hrombus in the left anterior descending coronary artery was
ocumented.
Twelve-lead ECGs were recorded on admission at a paper
peed of 25 mm/s and an amplification of 10 mm/mV. ST-
egment deviation from the baseline PR segment was measured 80
s after the J point and was considered present if deviation was
0.5 mm in limb leads and 1.0 mm in precordial leads. The
natomically contiguous Cabrera sequence (III, aVF, II, aVR, I,
nd aVL) was used to display the limb leads, as recommended in
urrent international clinical interpretation for electrocardiography
3). The QTc interval was calculated using Bazett’s formula. We
lso analyzed the following admission electrocardiographic find-
ngs, previously shown to be associated with TC (4): absence of
eciprocal changes (defined as ST-segment depression in at least 2
nferior leads) and absence of abnormal Q waves. Comparisons of
ontinuous variables were analyzed with a t test. Categorical
ariables were compared by the chi-square test.
Patients with TC were older (age 70  11 years vs. 61  11
ears, p  0.001), were more likely to be women (85% vs. 15%,
 0.001), and had a longer time from symptom onset to
dmission (3.4  2.0 h vs. 2.7  1.8 h, p  0.03) than did those
ith anterior AMI. TC was associated with a shorter R-R interval
657  116 ms vs. 791  164 ms, p  0.001), a lower maximal
T-segment elevation (4.5  4.9 mm vs. 7.0  3.0 mm, p 
.001), and a greater number of leads with ST-segment elevation o7.5 2.1 vs. 6.3 2.0, p 0.001), compared with anterior AMI.
C was more frequently associated with ST-segment elevation in
eads III, aVF, II,aVR, and I, especially leadaVR, and was less
requently associated with ST-segment elevation in leads aVL and
1 to V4, especially lead V1 (Fig. 1A). TC was also more
requently associated with the absence of abnormal Q waves (42%
s. 26%, p 0.048), absence of reciprocal changes (94% vs. 51%, p
.001), and a longer maximal QTc interval (567  81 ms vs. 489 
1 ms, p  0.001). The absence of abnormal Q waves, absence of
eciprocal changes, presence of ST-segment elevation in lead
aVR (i.e., ST-segment depression in lead aVR), and absence of
T-segment elevation in lead V1 identified TC with sensitivities of
2%, 94%, 97%, and 94%, specificities of 74%, 49%, 75%, and
1%, and predictive accuracies of 71%, 53%, 77%, and 73%,
espectively. The combination of the presence of ST-segment
epression in lead aVR and the absence of ST-segment elevation
n lead V1 identified TC with 91% sensitivity, 96% specificity, and
5% predictive accuracy, which was superior to any other electro-
ardiographic findings (Fig. 1B).
Time to presentation may determine electrocardiographic pre-
entation. To clarify electrocardiographic characteristics of TC, we
tudied only patients who were admitted within 6 h of symptom
nset. Moreover, most previous studies assessing electrocardio-
raphic findings of TC have paid little attention to limb leads. We
herefore evaluated the frequencies of ST-segment elevation in all
2 leads (treating lead aVR as lead aVR). Compared with
nterior AMI, TC was associated with less ST-segment elevation
nd more frequent absence of abnormal Q waves, suggesting less
yocardial damage. Nevertheless, in TC, ST-segment elevation
as more extensive, involving not only the anterior region. Most
atients with anterior AMI had ST-segment elevation in leads V1
o V4, indicating ischemia of the anteroseptal region. The extent of
T-segment elevation in anterior AMI may reflect the extent of
rea at risk. In TC, ST-segment elevation most frequently oc-
urred in lead aVR. The display of lead aVR (150°) is inverted
ecause leadaVR (30°) bridges the gap between lead I (0°) and
ead II (60°). LeadaVR faces the apical and inferolateral regions,
hich none of the standard 12 leads face directly. In anterior AMI,
he perfusion territory of the left anterior descending coronary
rtery usually does not extend to these regions; therefore, the
revalence of ST-segment elevation in lead aVR is low. Inter-
stingly, diffuse ST-segment elevation (most prominently in lead
aVR) in TC is thought to reflect the extensive distribution of
all-motion abnormalities centered around the apex, extending
eyond the perfusion territory of any single coronary artery. On the
ther hand, ST-segment elevation was rare in lead V1, which may
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June 1, 2010:2514–7ace the right ventricular anterior region as well as the right
araseptal region. The most likely reason for less ST-segment
levation in lead V1 in TC is that wall-motion abnormalities in TC
arely extend to the region faced by lead V ; moreover, less
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Figure 1 Comparisons of Admission Electrocardiographic Findings Betw
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T-segment elevation may result from the electrical force induced cy ST-segment elevation in the posterolateral region (3). One can
peculate that TC, but not anterior AMI, is usually associated with
T-segment elevation in the posterolateral region.
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June 1, 2010:2514–7dmitted within 6 h of symptom onset. Further studies in larger
umbers of patients are needed to verify our results.
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2003;67:687–90.Letter to the Editorigh-Dose Statin,
ot So IDEAL?
ikkanen et al. (1) present an interesting post-hoc analysis of the
DEAL (Incremental Decrease in Endpoints Through Aggressive
ipid Lowering) study with a novel statistical method using all
ascular rather than just the first cardiovascular events recorded, and
hey propose highly significant p values in support of using top-dose
torvastatin (80 mg/day) versus “standard” dose simvastatin (20
g/day or uptitrated). The authors propose that such a statistical
pproach is of value because of the health economic importance of
ubsequent events, and that their results “suggest that clinicians should
ot hesitate to prescribe high-dose statin therapy for patients experi-
ncing multiple recurrent cardiovascular events.”
The background: The IDEAL study was an apparently well-
un, open-label drug comparison trial in all post-myocardial infarct
MI) patients, of whom about 40% had already experienced
evascularization and an 8.3% mortality rate (0.1% between
roups) during the mean 4.8 years of follow-up. The lack of
ortality benefit is in line with atorvastatin’s well-known inability
o lower mortality, with the notable findings of the TNT (Treating
o New Targets) trial and the SPARCL (Stroke Prevention by
ggressive Reduction in Cholesterol Levels) trial that ended with
umerically more deaths on top-dose atorvastatin than on low-
ose and placebo, respectively (2,3).
Since mortality is not reduced, we have to ask about the nature
f events prevented. The authors report that the first, second, and
hird events recorded were 46%, 51%, and 43% on the basis of
ecisions to hospitalize or to revascularize, whereas nonfatal MIsAnglo-Scandinavian Cardiac Outcomes Trial) study found angina
educed by 41%, likely by the nitric oxide/endothelial nitric oxide
ynthase nitroglycerin mimicking action that all statins share (4,5).
he amount of angina experienced is a factor potentially affecting
he medical decisions and the number of MIs recorded in a trial.
Thus, we have to be careful including these softer end points, and
ince the authors bring up health economics, we should be aware that
t the current (Vermont) retail prices of $5 per pill for “high
ose-statin” (Lipitor 80 mg and Crestor 20 mg), it would cost, as an
xample, from $560,000 to $1,160,000—slightly less in men, more in
omen—to prevent either a revascularization, stroke, or MI on the
asis of the results of the recent JUPITER (Justification for the Use of
tatins in Primary Prevention: An Intervention Trial Evaluating
osuvastatin) primary prevention study (rosuvastatin 20 mg vs.
lacebo) (6). Even at the current Vermont price for generic lovastatin
$0.78 for 20mg), such costs, likely even in secondary prevention, may
e many times those of an angioplasty, a hospitalization for angina, or
he cost of a (not clearly defined nor quantified by Tikkanen et al. [1])
eripheral vascular disease event.
These drug costs call into question the benefit of statins, including
igh-dose statin, regarding health economic benefits. Therefore,
ould the authors comment on the health economic effects of their
xpanded end point analysis, and provide numbers needed to treat for
ndividual end points, with confidence intervals?
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